Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Bhagwan Yadav, PhD, Mette Ilander, PhD, Anna Kreutzman, PhD, Henrik Hjorth-Hansen, MD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1602.

https://doi.org/10.1182/blood.V130.Suppl_1.1602.1602

Published: 2017

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Blood (2017) 130 (6): 789–802.

https://doi.org/10.1182/blood-2016-02-699363

Published: 2017

Includes: Supplemental data

Journal Articles

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Blood (2016) 128 (22): 2921.

https://doi.org/10.1182/blood.V128.22.2921.2921

Published: 2016

Journal Articles

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

Jarno Kivioja, MSc, Angeliki Thanasopoulou, PhD, Mika Kontro, MD, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Juerg Schwaller, MD, Caroline A Heckman, PhD

Blood (2016) 128 (22): 4711.

https://doi.org/10.1182/blood.V128.22.4711.4711

Published: 2016

Journal Articles

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen, Tea Pemovska, Muntasir Mamun Majumder, Bhagwan Yadav, Jing Tang, Mika Kontro, Bjørn Gjertsen, MD PhD, Alun Parsons, Minna Suvela, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Krister Wennerberg, Jonathan Knowles, Caroline Heckman

Blood (2015) 126 (23): 867.

https://doi.org/10.1182/blood.V126.23.867.867

Published: 2015

Journal Articles

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Pekka Antilla, David Tamborero, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjanna Säily, Bhagwan Yadav, MSc, Krister Wennerberg, PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2046.

https://doi.org/10.1182/blood.V124.21.2046.2046

Published: 2014

Journal Articles

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Muntasir Mamun Majumder, MSc, David Tamborero, PhD, Bhagwan Yadav, MSc, Mika Kontro, MD, Bjørn Gjertsen, MD PhD, Alun Parsons, MSc, Minna Suvela, BSc, Tero Aittokallio, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 3505.

https://doi.org/10.1182/blood.V124.21.3505.3505

Published: 2014

Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2160.

https://doi.org/10.1182/blood.V124.21.2160.2160

Published: 2014

Journal Articles

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Disha Malani, MSc, Astrid Murumägi, PhD, Bhagwan Yadav, MSc, Tea Pemovska, MSc, John Patrick Mpindi, MSc, Mika Kontro, MD, Tero Aittokallio, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD, Maija Wolf, PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 2163.

https://doi.org/10.1182/blood.V124.21.2163.2163

Published: 2014

Journal Articles

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Riikka Karjalainen, MSc, Tea Pemovska, MSc, Bhagwan Yadav, MSc, Muntasir Mamun Majumder, MSc, Mika Kontro, MD, Kimmo Porkka, MD, PhD, Olli Kallioniemi, MD, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD

Blood (2013) 122 (21): 1668.

https://doi.org/10.1182/blood.V122.21.1668.1668

Published: 2013

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Blood (2012) 120 (21): 288.

https://doi.org/10.1182/blood.V120.21.288.288

Published: 2012

NARROW

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies

Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma

Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only